Merrimack Pharmaceuticals Story

Merrimack Pharmaceuticals Inc -- USA Stock  

USD 10.82  0.08  0.74%

Macroaxis does not monitor all media channels or aggregates social signals for Merrimack Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Merrimack Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Merrimack Pharmaceuticals. Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance
Acquisition by John Mendelsohn of 7500 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by John Mendelsohn, the corporate stakeholder, on December 7, 2017. This event was filed by Merrimack Pharmaceuticals with SEC on 2017-09-15. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on December 7, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.95% . The trading delta at closing time when the story was published against the current closing price is 1.91% .

Similar stores for Merrimack Pharmaceuticals

a day ago at 
Acquisition by Jean Franchi of 45000 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Merrimack Pharmaceuticals officer. Grant, award or other acquisition pursuant to Rule 16b-3
over two weeks ago at 
Merrimack Pharmaceuticals Inc Holdings Cut by Schwab Charles Investment ...
patch News
Merrimack Pharmaceuticals logo Schwab Charles Investment Management Inc. lowered its stake in shares of Merrimack Pharmaceuticals Inc by 79.2 percent in the third quarter, according to the company in its most recent Form 13F filing with the ... -0.28 EPS Expected for Merrimack Pharmaceuticals, Inc. 11 Analysts ... - Key Gazette
over a month ago at 
A New Kind of Stock Chart Merrimack Pharmaceuticals Inc NASDAQMACK ...
This is a real time view of the critical technical pivot points for Merrimack Pharmaceuticals Inc . The technical pivot points we look at all surround the stock price movement from the last 10-trading days through the last year.

Did you try this?

Run Crypto Portfolio Optimizer Now

Crypto Portfolio Optimizer

Optimize portfolio of digital coins and token across multiple currency and exchanges
Hide  View All  NextLaunch Crypto Portfolio Optimizer

Cash and Equivalents

Cash and Equivalents Comparative Analysis
  Cash and Equivalents 
      Merrimack Pharmaceuticals Comparables 
Merrimack Pharmaceuticals is currently under evaluation in cash and equivalents category among related companies. Cash or Cash Equivalents are the most liquid of all assets found on company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.